Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SS)
Zhenjiang, CN
Jiangsu Jibeier Pharmaceutical Co., Ltd. is a pharmaceutical enterprise based in Zhenjiang, China, established in 2001. The company's core operations involve the research, development, manufacturing, and sales of a diverse range of pharmaceutical products, including chemical preparations, traditional Chinese medicine formulations, and active pharmaceutical ingredients (APIs). Its product portfolio addresses various health concerns, offering solutions for boosting white blood cell counts, enhancing the immune system, treating joint-related ailments, managing high blood pressure, combating ocular infections, alleviating bronchitis symptoms, and protecting liver function, among others. Additionally, Jiangsu Jibeier is actively engaged in developing new therapeutic drugs, with its pipeline focusing on treatments for conditions such as depression, oncology (tumors), and gastrointestinal disorders.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.29% | -6.16% | -10.25% | -12.59% | -14.55% | -15.81% | -6.93% | -30.00% | +1.58% | -45.01% | -45.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+7.6% ★ Q1'26: +12.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+15.0% Q1'26: -16.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+22.1% ★ Q1'26: -21.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+30.9% ★ Q1'26: +22.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+15.7% ★ Q1'26: +9.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.5% Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.06× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
654.73M
est: 652.00M (+0.4%)
|
860.93M
est: 861.00M (0.0%)
|
896.53M
est: 1.00B (-10.7%)
|
964.93M
est: 1.23B (-21.6%)
|
1.49B
1.49B – 1.49B
+21.4% YoY
|
| EBITDA |
187.66M
est: 176.16M (+6.5%)
|
258.93M
est: 232.63M (+11.3%)
|
264.20M
est: 357.77M (-26.2%)
|
308.81M
est: 438.31M (-29.5%)
|
532.03M
532.03M – 532.03M
+21.4% YoY
|
| EBIT |
174.91M
est: 164.00M (+6.7%)
|
247.72M
est: 216.56M (+14.4%)
|
253.60M
est: 363.00M (-30.1%)
|
298.21M
est: 444.72M (-32.9%)
|
539.81M
539.81M – 539.81M
+21.4% YoY
|
| Net Income |
154.67M
est: 130.04M (+18.9%)
|
219.09M
est: 221.27M (-1.0%)
|
219.33M
est: 272.22M (-19.4%)
|
258.67M
est: 334.66M (-22.7%)
|
414.03M
405.80M – 453.78M
+23.7% YoY
|
| SGA |
361.56M
est: 361.58M (0.0%)
|
459.86M
est: 477.49M (-3.7%)
|
458.54M
est: 440.87M (+4.0%)
|
—
est: 540.10M (-100.0%)
|
655.59M
655.59M – 655.59M
+21.4% YoY
|
| EPS |
0.83
est: 0.67 (+23.9%)
|
1.17
est: 1.14 (+2.6%)
|
1.13
est: 1.37 (-17.5%)
|
1.30
est: 1.71 (-24.0%)
|
2.16
2.04 – 2.28
+26.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 80.7K | 0.39% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 14.9K | 0.46% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 55.2K | 0.29% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 19.0K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haidao Li | Deputy Director of the Research Institute | — | male |
| Jianzhong Zhai | Board Secretary | — | male |
| Suofu Zhao | Financial Director | — | male |
| Xinjun Yu | Vice Chairman of the Board & Deputy GM | — | male |
| Xiugen Wu | Institute Director | — | male |
| Xufeng Qin | Deputy Director of the Research Institute | — | male |
| Ying Wu | Deputy General Manager | — | female |
| Zhaoguang Li | Director of the Synthesis Office of the Research Institute | — | male |
| Zhi Lei Zhu | Accounting Supervisor | — | — |
| Zhongyi Geng | GM & Chairman of the Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688566.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
